-----------FRAUD EMAIL ALERT-----------------
We have heard a number of reports of ISPE members receiving emails claiming to be from ISPE President Jesper Hallas.
Any email from ISPE or Professor Jesper Hallas asking for travel money is fraudulent.
Do not respond or answer.
A few people have shared that they received emails from "Professor Jesper Hallas" asking for money to attend a funeral. The email comes from a "@zoho.com" email address. This is not his email address but a mailbox created to look like his email.
If you have any questions, contact the ISPE office at +1.301.718.6500 or firstname.lastname@example.org. For details on phishing and how these scams work, visit this link from the U.S. Federal Trade Commission.
The FDA held a public workshop on September 18, 2017 on Benefit-Risk Assessments in Drug Regulatory Decision-Making. The docket for the meeting is open for public comments and closes November 18, 2017. A group of individuals within the BRACE SIG, led by Brett Hauber, has composed a set of recommendations for which the group is seeking ISPE Board approval through the expedited policy process. Under the expedited policy, members have 3 business days to submit comments on the policy.
ISPE is now accepting abstracts for oral/poster presentations in the area of pharmacoepidemiology and drug safety for our 2018Mid-Year Meeting, which will be held at the Sheraton Centre Toronto Hotel, April 21-24, 2018.
Current full-time students that are lead author on the study are invited to submit abstracts for presentation at this meeting. Twelve student abstracts will be selected for oral presentations at the meeting in Toronto.
Upcoming Webinar: Taking a Global View on Risk Minimization Programs
The BRACE SIG will be presenting the webinar "Taking a Global View on Risk Minimization Programs: Harmonizing Core vs. Regional Commitments. What is essential? What is adaptable?" on October 10, 1:00 PM (Eastern Time). This 2-part webinar will: 1) discuss scientific considerations in the local adaptation of risk minimization interventions using best practices from implementation science; and, 2) provide pragmatic recommendations for harmonization and successful implementation of risk minimization programs across differing geographic locales. Pharmaceutical risk minimization case examples will be presented to illustrate real-world challenges and solutions for global drug programs. Click here to register for the webinar using the Webinar ID: 697-309-651
2018 ICPE Call for Topics - Deadline October 12
ISPE is seeking ideas for potential plenary, keynote, and hot topics sessions for the 2018 ICPE, which will be held August 22-26, 2018 in Prague, The Czech Republic. The annual conference is developed organically from the interests of those within the Society with all ISPE members welcome to contribute. Members are invited to complete our online form by October 12th with suggestions for topics and speakers.
The Core Scientific Committee will look for suggestions that have broad applicability across the ISPE constituency; include perspectives that are historical, forward thinking, and/or offer applicable insights from other fields of study; and that encourage engaging and provocative discussion for the purpose of advancing the field. Potential topics will be reviewed by the 2018 ICPE Core Scientific Committee and considered for inclusion in the Prague program. The Committee will contact you if additional information is needed.
ISPOR/ISPE Summit on Real-World Evidence in Health Care Decision Making, October 20, 2017, Washington, DC
ISPOR and ISPE have collaborated on a joint task force to produce coordinated papers that make specific recommendations for improving the transparency and reproducibility of real-world evidence for use in health care decision making-especially those decisions at the regulatory and payer levels. This 1-day Summit will provide a forum for reviewing these task force reports, considering the perspectives of key stakeholders, and discussing future steps that could help enable these recommendations. click here for more information.